What Changed
Price Move History
- Daily moves over 5%
- 84 252 sessions, November 17, 2025 to November 17, 2026
- Largest daily move
- -42.1% close of March 31, 2026
- 1-year change
- -86.6% closing prices, November 17, 2025 to November 17, 2026
- 1-month change
- -7.3% closing prices, October 16, 2026 to November 17, 2026
Company Description
FibroBiologics, Inc. (FBLG) is a clinical-stage biotechnology company listed on the Nasdaq Capital Market that focuses on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. Based in Houston, the company describes itself as advancing cell therapy and tissue regeneration through fibroblast-based approaches, supported by an intellectual property portfolio of more than 270 issued and pending patents in the United States and internationally.
According to the company’s public statements, FibroBiologics is building a pipeline of treatments across multiple chronic disease areas. Its patent and research programs span clinical pathways that include wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. The company characterizes its work as representing a next generation of medical advancement in cell therapy and tissue regeneration, with fibroblast cells and fibroblast-derived materials at the core of its strategy.
Business focus and therapeutic areas
FibroBiologics’ business is centered on the discovery and development of fibroblast-based therapies. The company reports that it is pursuing programs in:
- Wound healing, including a fibroblast-based spheroid product candidate (CYWC628) for diabetic foot ulcers.
- Multiple sclerosis, where it is advancing a candidate known as CYMS101 toward an Investigational New Drug (IND) submission, supported by remyelination data in brain tissue repair models.
- Disc degeneration and orthopedics, including degenerative disc disease and broader musculoskeletal indications.
- Psoriasis, through CYPS317, an allogeneic fibroblast spheroid-based therapy for moderate to severe psoriasis, for which the company has filed a Phase 1/2 IND application with the U.S. Food and Drug Administration.
- Human longevity and cancer, including programs involving bone marrow organoid platforms and approaches to address age-related immune decline and tumor biology.
The company reports that it uses both engineered organoids and native fibroblast spheroids as part of a differentiated platform, and that its preclinical work includes evaluating mechanisms such as extracellular matrix remodeling, tissue support, and immunomodulation in various disease models.
Clinical-stage development and early programs
FibroBiologics describes itself as clinical-stage and has disclosed several key development milestones. For its wound healing program, the company completed CYWC628 master and working cell banks manufactured under FDA current good manufacturing practice (cGMP) standards with Charles River, which passed safety tests. It also received Human Research Ethics Committee (HREC) approval in Australia for a Phase 1/2 clinical trial of CYWC628 in diabetic foot ulcers, designed as a 120-patient study across multiple sites to evaluate safety, tolerability, and efficacy.
In psoriasis, the company cites positive IND-enabling data for CYPS317 spheroids, including efficacy in acute and chronic preclinical models, and has filed an IND application with the FDA to initiate clinical trials in patients with moderate to severe disease. For multiple sclerosis, FibroBiologics reports remyelination in brain tissue repair models and is advancing CYMS101 toward an IND submission. The company also notes preclinical work in bone marrow organoids for cancer and age-related immune decline as part of its human longevity program.
Regenerative medicine and FSdC spheroid platform
FibroBiologics has announced preclinical results for a fibroblast spheroid-derived chondrocyte (FSdC) spheroid therapy targeting degenerative disc disease. In animal models, the company reports that FSdC spheroids improved intervertebral disc height recovery and structural integrity compared with other fibroblast-based approaches, with statistically significant differences from vehicle control and favorable disc height indices over a 12-week study period. The company describes this as a significant step in its regenerative medicine pipeline and as evidence of potential to address unmet needs in spinal health.
In addition, FibroBiologics has filed a U.S. patent application titled “Spheroids For Cartilage Repair,” covering a fibroblast-derived therapy platform for orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration. The application is described as strengthening protection for technology that uses fibroblast cells, spheroids, and fibroblast-differentiated chondrocyte spheroids to support structural and functional repair in orthopedic tissues.
Intellectual property and platform scope
The company emphasizes intellectual property as a central asset. Public disclosures state that FibroBiologics holds more than 270 issued and pending patents across the U.S. and internationally. These patents and applications cover areas such as wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer, as well as methods for generating multipotent cells from donor fibroblasts, modulating mitochondrial activity using fibroblasts, and fibroblast-based chondrocyte spheroid platforms.
FibroBiologics characterizes its IP portfolio as covering fibroblast cells and fibroblast-derived materials across a range of potential indications, including chronic inflammatory diseases, musculoskeletal disorders, and age-related conditions. The company has also referenced earlier filings related to cancer treatments and preventing blood clotting in cell therapies.
Facilities and operations
In its communications, FibroBiologics notes that it has expanded its laboratory footprint in Houston with a facility designed to support discovery and in-house manufacturing. The company links this expansion to its ability to scale fibroblast-based platforms, hire additional scientific staff, and accelerate research and development activities. It also reports participation in scientific and investor conferences and the publication of opinion pieces discussing the therapeutic potential of fibroblast cells compared with other cell therapy approaches.
Capital markets activity and Nasdaq listing
FibroBiologics’ common stock trades on the Nasdaq Capital Market under the ticker symbol FBLG. The company has used a variety of equity financing structures, including registered direct offerings, concurrent private placement warrants, and a Standby Equity Purchase Agreement. Recent filings describe offerings of common stock and warrants, including transactions where proceeds were received in sovereign-issued gold coins and then intended to be converted into U.S. dollars.
The company has disclosed notices from Nasdaq regarding non-compliance with certain continued listing standards, including the minimum bid price requirement and the minimum Market Value of Listed Securities threshold. These notices did not immediately affect the listing of the company’s common stock, and FibroBiologics has stated that it may consider available options to regain compliance. A special meeting proxy statement describes a proposed reverse stock split within a specified ratio range, as well as proposals to approve the issuance of shares underlying various warrant agreements, in accordance with Nasdaq Listing Rule 5635(d).
Corporate governance and stockholder matters
FibroBiologics is incorporated in Delaware. Proxy materials describe a special meeting of stockholders to be held virtually, with proposals including a reverse stock split amendment, approvals for share issuances related to securities purchase agreements and engagement letters, and an adjournment proposal. The proxy statement also explains that shares of Series C Preferred Stock with super voting rights are outstanding and that an irrevocable proxy grants the board of directors the right to vote those preferred shares on most matters, subject to specified limitations.
Position within biotechnology and cell therapy
Within the biotechnology sector, FibroBiologics positions itself as a company focused on fibroblast-based cell therapies and fibroblast-derived materials for chronic diseases. Its disclosed programs span chronic inflammatory conditions, neurodegenerative and demyelinating diseases, musculoskeletal and orthopedic disorders, wound healing, oncology, and longevity-related biology. Investors evaluating FBLG as a biotechnology stock can review the company’s public filings and news releases for details on its clinical trial plans, preclinical data, financing arrangements, and stockholder proposals.
Stock Performance
FibroBiologics (FBLG) closed at $0.9005 on November 17, 2026. Over the past 12 months, the price has lost 86.6%.
FBLG Metrics & Rankings
Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
FibroBiologics has 10 recent news articles, with the latest published on . Of the recent coverage, 2 articles coincided with positive price movement and 7 with negative movement. Key topics include earnings, private placement. View all FBLG news →
SEC Filings
FibroBiologics has filed 10 recent SEC filings, including 2 Form EFFECT, 2 Form POS AM, 2 Form 8-K, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all FBLG SEC filings →
Financial Highlights
FibroBiologics reported operating income of -$16.6M in FY2025, and net income was -$18.6M. Diluted earnings per share stood at -$8.40. The company generated -$16.4M in operating cash flow. The current ratio was 3.61, measuring current assets divided by current liabilities.
Upcoming Events
Investor webinar presentation
Sentinel safety readout
CYWC628 primary data
Interim efficacy readout
Warrant Expiration
FibroBiologics has 5 upcoming scheduled events. The next event, "Investor webinar presentation", is scheduled for November 19, 2026 (tomorrow). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the FBLG stock price.
Short Interest History
Short interest in FibroBiologics (FBLG) currently stands at 334.1 thousand shares, up 1.1% from the previous reporting period, representing 5.6% of the float. Since the latest stock split, short interest has increased by 234.2%, measured from April 2026.
Days to Cover History
Days to cover for FibroBiologics (FBLG) currently stands at 3.1 days, up 32.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 212%. Across the settlements charted above, it has ranged from 1.0 to 3.8 days.
FBLG Company Profile & Sector Positioning
FibroBiologics (FBLG) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing FBLG often look at related companies in the same sector, including Enveric Biosciences, Inc. (ENVB), GT Biopharma Inc. (GTBP), Theriva Biologics, Inc. (TOVX), Curanex Pharmaceuticals Inc (CURX), and Alaunos Therapeutics, Inc. (TCRT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate FBLG's relative position within its industry.